Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21468597 | 0.87 | SOS1 (0.53) | MAPK14SOS1APPSMN1; SMN2NPC1 | |
| SCHEMBL13042657 | 0.80 | RAB9A (0.59) | MAPK14SOS1EGFRSMN1; SMN2NPC1 | |
| SCHEMBL29980421 | 0.78 | RAPGEF4 (0.49) | KDREGFRRAPGEF4ALDH1A1LMNA | |
| SCHEMBL12266353 | 0.78 | RAPGEF4 (0.49) | KDREGFRRAPGEF4ALDH1A1LMNA | |
| SCHEMBL22864084 | 0.77 | MAPK14 (0.59) | MAPK14SMN1; SMN2NPC1RAB9ARAPGEF4 | |
| SCHEMBL28689644 | 0.77 | LMNA (0.61) | SMN1; SMN2NPC1RAB9AHTTGAA | |
| Hydrochloric Acid SCHEMBL27087418 | 0.77 | RAPGEF4 (0.47) | KDREGFRRAPGEF4ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL29980355 | 0.77 | RAPGEF4 (0.47) | KDREGFRRAPGEF4ALDH1A1LMNA | |
| SCHEMBL14137199 | 0.75 | EGFR (0.57) | EGFRRAPGEF4GAAALDH1A1LMNA | |
| SCHEMBL1687027 | 0.74 | RAPGEF4 (0.61) | KDREGFRRAPGEF4GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379234-B1 | HALOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF | NOVARTIS AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| US-6919336-B2 | Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of IL-1 and TNF | NOVARTIS AG (CH) | 2005-07-19 | — | — | US | disclosed |
| US-20040097731-A1 | Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1and tnf | NOVARTIS AG (CH) | 2004-05-20 | — | — | US | disclosed |
| EP-1379234-A1 | HALOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF | Novartis AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002076447-A1 | HALLOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097731-A1 | Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1and tnf | TNF, NFKBIA, IL1A | MAPK14 35/4885KDR 1399/4885SOS1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.